ClinicalTrials.gg
WithdrawnNCT02421029Updated Aug 29, 2017

Prolonged Gadolinium Retention After MRI Imaging

A Phase 4 interventional study of edetate calcium disodium in Heavy Metal Toxicity, sponsored by Mt. Sinai Medical Center, Miami. Withdrawn at 1 site in United States. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-29.

Sponsored by Mt. Sinai Medical Center, Miami · Phase 4, Interventional, and Diagnostic

How we know

Why this study was withdrawn
it was logistically difficult to obtain the drug needed to conduct the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The researchers propose to investigate the prevalence of gadolinium in the urine of patients with a prior gadolinium-enhanced MRI before and after a edetate calcium disodium challenge. Moreover, will investigate if there is any correlation of gadolinium urine levels with levels of endogenous (e.g zinc) and xenobiotic metals.

Read the detailed description

The investigators propose to enroll 20 volunteers in this pilot study, including males older than 20 years and postmenopausal women in two groups: Group 1: Individuals who had a gadolinium-enhanced MRI study within 1-4 weeks before participation and Group 2: Individuals who had gadolinium-enhanced MRI study within 3-6 months before enrollment. The results will inform future analyses of gadolinium retention, excretion, and potential symptoms associated with same.

Thus, the specific aims of this cross sectional study are to:

  1. Evaluate levels of gadolinium in the urine of adults with normal kidney function and a prior MRI performed within 6 months at baseline, and after a single dose of edetate calcium disodium .
  2. Evaluate levels of endogenous and xenobiotic metal levels and their relationship with gadolinium levels.
  3. Evaluate for symptoms of gadolinium toxicity.
02

Conditions studied

  • Heavy Metal Toxicity

Keywords

  • gadolinium
  • calcium disodium ethylenediaminetetraacetic acid (EDTA)
  • heavy metal toxicity
03

In context

Lead sponsor

Mt. Sinai Medical Center, Miami is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who had a contrast enhanced MRI for any indication within 1-4 weeks or 3-6 months, and normal renal function assessed by normal (GFR) >60 mL/min/1.73 m2 at the time of the gadolinium-enhanced MRI study.

Exclusion criteria

Exclusion Criteria:

  • Allergy to edetate calcium disodium
  • Prior chelation therapy with edetate disodium since the administration of gadolinium
  • Blood pressure >160/100
  • No venous access
  • count \<100,000/mm3
  • Liver disease or (ALT) or aspartate transaminase (AST) >2.0 times the
  • Diseases of copper, iron, or calcium metabolism
  • Women of
  • History of lead intoxication; lead encephalopathy; cerebral edema.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    edetate calcium disodium

    Subjects who had a gadolinium-enhanced MRI within 1-4 weeks or within 3-6 months before enrollment will receive a single dose of edetate calcium disodium to evaluate levels of gadolinium in their urine, pre and post infusion.

    Drug: edetate calcium disodium

Interventions

  • DrugEdetic AcidStudies of Edetic AcidEdetic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium

    Also known as: Calcium Disodium Versenate

06

What researchers measure

Primary outcomes

  1. gadolinium levels in urine before and after an edetate calcium disodium challenge

    Time frame: within 6 months of a gadolinium-enhanced MRI

07

Study locations

1 site
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2017; primary completion for Dec 2018, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2015
First posted
Apr 20, 2015
StartEst.
Jul 2017
Primary completionEst.
Dec 2018
CompletionEst.
Dec 2018
Last update
Aug 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02421029
Lead sponsor
Mt. Sinai Medical Center, Miami
Responsible party
Gervasio Lamas, MD (Chair, Department of Medicine, Mt. Sinai Medical Center, Miami) — Principal investigator
First posted
Apr 20, 2015
Start date
Jul 2017 (estimated)
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Aug 29, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edetic Acid

Start the discussion